Marksans Pharma Limited has informed the Exchange about Investor Presentation
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma delivered a milestone year in FY26 with total income of Rs 3,033 crore (up 12.8% YoY), EBITDA of Rs 601 crore at 20.4% margin, and PAT of Rs 420 crore. Q4FY26 showed strong sequential improvement with EBITDA margin expanding 152bps to 22.8%. The company crossed Rs 3,000 crore revenue milestone, cash balance stands at Rs 990 crore, and it remains net cash positive for over 5 years. Key growth drivers include 112 new SKU launches in the US market, entry into new geographies (Germany, Canada, Ireland), and the launch of 11 Rx branded products in Australia under Nova Pharma. US remains the largest market contributing 52% of revenue at Rs 1,533 crore with 24% growth. Management noted it is monitoring emerging input cost pressures but remains confident in sustained growth given strong balance sheet and disciplined execution.
The company met all its FY26 guidance targets and demonstrated consistent execution. Strong cash position (Rs 990 crore) and expanding margins (EBITDA margin rose to 22.8% in Q4) position the company well for continued growth and potential value-accretive acquisitions in Europe. The multi-year track record of meeting guidance should boost investor confidence.